Sequoia Vaccines, Inc. products

Sequoia is developing a vaccine to reduce the recurrences of Urinary Tract Infections (UTI). Sequoia has completed its first clinical study in women with and without a history of recurrent UTI. In this study, Sequoia`s investigational vaccine was highly immunogenic and well tolerated.  In addition, it appears that the vaccine may indeed reduce the frequency of UTI.  These preliminary results are from an uncontrolled Phase 1 clinical trial that enrolled 67 women ages 21 to 64.  Of the 67 women enrolled, 30 had a 2-year documented history of recurrent UTI.  Based on these positive Phase 1 results, the vaccine is proceeding to a placebo-controlled Phase 2 study.

Sequoia is developing an anticancer compound (SQ1274) for use against solid tumors including ovarian and lung cancers.